Search Within

Eytan Moshe Stein

Formats
  1. Meeting Abstract (217)
  2. Journal Article (109)
  3. Review (18)
  4. Research Letter (14)
  5. Editorial (6)
  6. Book Section (3)
  7. Guidelines (2)
  8. Correspondence (1)
  9. Miscellaneous (1)
Groups
  1. Adult Leukemia (371)
  2. Center for Hematologic Malignancies (371)
  3. Department of Medicine (371)
  4. Hematologic Malignancies, Division of (371)
  5. Hematology-Oncology Fellows (111)
  6. GSK Faculty (92)

More Groups

People
  1. Martin Tallman (118)
  2. Ross Levine (75)
  3. Aaron Goldberg (43)
  4. Andriy Derkach (33)
  5. Jan Bewersdorf (33)
  6. Christopher Famulare (31)

More People

Years
  1. 2025 (20)
  2. 2024 (45)
  3. 2023 (49)
  4. 2022 (34)
  5. 2021 (31)
  6. 2020 (30)

More Years

Publications
  1. Blood (171)
  2. Journal of Clinical Oncology (23)
  3. Clinical Lymphoma, Myeloma and Leukemia (18)
  4. Haematologica (16)
  5. Blood Advances (14)
  6. Leukemia and Lymphoma (12)

More Publications

Publishers
  1. American Society of Hematology (186)
  2. Elsevier Inc. (32)
  3. American Society of Clinical Oncology (28)
  4. Ferrata Storti Foundation (16)
  5. Nature Publishing Group (15)
  6. Taylor & Francis Group (12)

More Publishers

Results (371)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors
    Journal Article

    Bewersdorf, J. P.; Shallis, R. M.; Derkach, A.; Goldberg, A. D.; Stein, A.; Stein, E. M.; Marcucci, G.; Zeidan, A. M.; Shimony, S.; DeAngelo, D. J.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Routine clinical parameters and laboratory testing predict therapy-related myeloid neoplasms after treatment for breast cancer
    Journal Article

    Petrone, G.; Gaulin, C.; Derkach, A.; Kishtagari, A.; Robson, M. E.; Parameswaran, R.; Stein, E. M.
    Haematologica (2023)

    Fulltext@MSK | Save
  • IDH2 inhibition in AML
    Editorial

    Stein, E. M.
    Blood (2023)

    Fulltext@MSK | Save
  • Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia
    Journal Article

    Stahl, M.; Derkach, A.; Farnoud, N.; Bewersdorf, J. P.; Robinson, T.; Famulare, C.; Cho, C.; Devlin, S.; Menghrajani, K.; Patel, M. A.; more...
    American Journal of Hematology (2023)

    Fulltext@MSK | Save
  • SELECT-AML-1 trial in progress: A phase 2 study of tamibarotene in combination with venetoclax and azacitidine in previously untreated adult patients selected for RARA-positive AML who are ineligible for standard induction therapy
    Meeting Abstract

    Kambhampati, S.; Eghtedar, A.; McMahon, C.; de Botton, S.; Pigneux, A.; Ball, B.; Borthakur, G.; Angela, V.; Gausman, J. A.; Baker, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Trial in progress: Phase Ib/II study of siremadlin in combination with venetoclax plus azacitidine in patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy (IC)
    Meeting Abstract

    Daver, N. G.; Wei, A. H.; Stein, E. M.; DeAngelo, D. J.; Pathak, D.; Xu, Y. N.; Grzesiak, S.; Venditti, A.
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Overall survival (OS) by IDH2 mutant allele (R140 or R172) in patients with late-stage, mutant-IDH2 relapsed/refractory acute myeloid leukemia (AML) treated with enasidenib or conventional care regimens (CCR) in the randomized, open-label, phase 3 IDHENTIFY trial
    Meeting Abstract

    DiNardo, C. D.; de Botton, S.; Risueño, A.; Schuh, A. C.; Lowenberg, B.; Kim, H. J.; Vyas, P.; Wei, A. H.; Stein, E. M.; Döhner, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • First results of a phase II study (STIMULUS-AML1) investigating sabatolimab plus azacitidine plus venetoclax in patients with newly diagnosed acute myeloid leukemia (ND AML)
    Meeting Abstract

    Zeidan, A. M.; Westermann, J.; Kovacsovics, T.; Assouline, S.; Schuh, A. C.; Kim, H. J.; Macias, G. R.; Sanford, D.; Luskin, M. R.; Stein, E. M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Outcomes based on sequential use of venetoclax based therapy and targeted therapy in acute myeloid leukemia (AML)
    Meeting Abstract

    Stahl, M.; Shallis, R. M.; Derkach, A.; Goldberg, A. D.; Stein, A.; Stein, E. M.; Marcucci, G.; Zeidan, A. M.; Shimony, S.; DeAngelo, D. J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Siremadlin in combination with venetoclax (VEN) plus azacitidine (AZA) in adult patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy: A phase Ib/II trial
    Meeting Abstract

    Daver, N.; Wei, A. H.; Stein, E.; DeAngelo, D. J.; Pathak, D.; Xu, Y.; Grzesiak, S.; Venditti, A.
    Blood (2022)

    Fulltext@MSK | Save